# Ailomics Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ailomics-therapeutics

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Latest round: Angel (Sep 19, 2022)
- Investors on record: 3

## About

Based in Shanghai, China, and founded in 2022, Ailomics Therapeutics operates as a developer of innovative drugs. It has established a new drug development center in Shanghai. The founder and CEO, Dr. Qing Zhang spent 14 years at GSK, Amgen, and Roche, where he worked on small molecule and antibody drug design, target discovery, and validation. The co-founder Dr. Ting Ban worked at Roche and Amgen.

Through deep learning and other AI technologies, the company analyzes multi-omics big data (including single cell and spatial histology) from patients to discover key cell types and intra- and extracellular signaling pathways that lead to disease progression, and select new targets that have the potential to address clinical needs for the development of First-in-class drugs.

## Funding rounds

- Angel, Sep 19, 2022 — Qiming Venture Partners, Trinity Innovation Fund, Huatong Capital

## Investors

- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Angel
- Trinity Innovation Fund (https://capitalatlas.ai/funds/trinity-innovation-fund) — Angel
- Huatong Capital — Angel